Search Results for: GNPX

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, is a potential target and biomarker for … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma”

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering”

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock. According … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s Oncoprex(TM) immunogene therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso(R)). Tagrisso(R), with worldwide sales … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its plans to attend and present at the Biotech Showcase(TM) 2020, to be held at the Hilton San Francisco Union Square in San Francisco from January 13–15, 2020. Genprex’s President … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Biotech Showcase(TM) 2020 in San Francisco”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, on Wednesday announced a registered direct offering of 3,167,986 shares of its common stock at a price of $0.40 each, for gross proceeds of about $1.26 million prior to deduction of commissions and offering expenses. In a concurrent private placement, Genprex agreed to issue unregistered warrants to … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $1.26M Registered Direct Offering”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced that it is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness in support of November’s Lung Cancer Awareness Month. According to the update, each case is unique, but several preventative actions may lower the risk of … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced its plans to present at the upcoming inaugural MicroCap Rodeo Investor Conference to be held at the Hilton Austin – Downtown in Austin, Texas. Genprex’s presentation is scheduled to take place on Tuesday, October 15 at 9:10 a.m. Central Time, led by its Chairman and CEO … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference”

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-8),” by researchers in Australia, Spain and Austria, supports the … Continue reading “QualityStocksNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Pioneering Use of Non-Viral Vector Delivery for Gene Therapy Validated by Additional Industry Research”